MET and hepatocellular carcinoma: After treatment with sorafenib, HGF secretion was decreased in macrophages, which reduced the polarized macrophage-conditioned medium-induced activation of HGF-Met signaling in hepatocellular carcinoma cells but not in normal liver cells.